November 06, 2020
Theratechnologies Announces That Data On The Mechanism Of Effect Of Tesamorelin In NAFLD Will Be Presented At The Liver Meeting® 2020
Montreal, Canada – November 6, 2020 – Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that an oral presentation including data on the mechanism of effect of tesamorelin in nonalcoholic fatty liver disease (NAFLD) will be given by Lindsay T Fourman, MD, of the Metabolism Unit, Department of Medicine, Massachusetts General Hospital, at The Liver Meeting® 2020 of the American Association for the Study of Liver Diseases (AASLD) to be held November 13-16, 2020.
Presentation Title: TREATMENT WITH GROWTH HORMONE RELEASING HORMONE ANALOG REDUCES VEGFA, TGFβ1, AND CSF1: MECHANISMS OF TESAMORELIN EFFECT IN NONALCOHOLIC FATTY LIVER DISEASE
Abstract Number: 0142
Session Broadcast Date and Time: Monday, November 16, 2020, 9:00 AM